



*Published by the  
N.J. Dept. of Human Services,  
Div. of Medical Assistance & Health Services  
& the N.J. Dept. of Health & Senior Services  
Div. of Senior Affairs*

# Newsletter

Volume 10 No. 74

September 2000

- TO:** Providers of Pharmaceutical Services – **For Action**  
Health Maintenance Organizations – For Information Only
- SUBJECT:** UPDATING OF NEWSLETTER VOLUME 10, No. 59, DATED AUGUST 2000 —“Additions and Deletions to the Medicaid and NJ KidCare Drug Rebate Programs Manufacturers’ Labeler Code List (APPENDIX F)”
- PURPOSE:** *To notify providers of pharmaceutical services and health maintenance organizations to update Newsletter Volume 10, No. 59, dated August 2000.*
- EFFECTIVE:** IMMEDIATELY
- BACKGROUND:** Newsletter Volume 10, No. 59, dated August 2000, was intended to notify providers of pharmaceutical services of changes to the additions and deletions to the Medicaid and NJ KidCare Drug Rebate Programs “Manufacturers’ Labeler Code List”.
- ADDITIONS:** The Manufacturers’ Labeler Codes listed below were **added** to the New Jersey Medicaid and the NJ KidCare fee-for-service programs as of the indicated effective date:

<u>LABELER</u>	<u>MANUFACTURER</u>	<u>EFFECTIVE DATE</u>
08290	BD Becton Dickinson	04/28/2000
60242	Neil Laboratories, Inc.	04/24/2000
64248	Women First Healthcare, Inc.	04/24/2000
65086	Santen Incorporated	04/24/2000
65473	Odyssey Pharmaceutical, Inc.	04/18/2000

**DELETIONS:** The Manufacturers' Labeler Codes listed below were **deleted** from the New Jersey Medicaid and the NJ KidCare fee-for-service Programs. Drugs manufactured by the manufacturer **will not be reimbursed** by Medicaid or NJ KidCare fee-for-service as of the indicated date:

<b><u>LABELER</u></b>	<b><u>MANUFACTURER</u></b>	<b><u>EFFECTIVE DATE</u></b>
37937	Medalist	10/01/2000
54921	IPR Pharmaceuticals, Inc.	07/01/2000
57783	Bristol-Meyers Squibb Company	07/01/2000
62174	ProMetic Pharma USA, Inc.	07/01/2000
62436	Bioglan Pharma, Inc.	07/01/2000
64836	Women's Capital Corporation	07/01/2000

If you have any policy questions concerning this Newsletter, please do not hesitate to contact the Chief, Pharmaceutical Services, DMAHS, at (609) 588-2724.

**RETAIN THIS NEWSLETTER NUMERICALLY BEHIND THE NEWSLETTER TAB  
(BLUE TAB MARKED "5")**